8.2 Clinical Trials, Research Protocols & Response Evaluation (RECIST)

Clinical Trials, Research Protocols & Response Evaluation (RECIST)

Clinical research drives the development of novel antineoplastic therapies, translating bench science into clinical practice. Advanced Practice Registered Nurses (APRNs) function as principal investigators, co-investigators, research nurse specialists, and advanced clinicians evaluating patients on clinical trials. Mastery of trial phases, ethical frameworks, adverse event grading, protocol compliance, and standardized objective response criteria (RECIST 1.1 and iRECIST) is essential for maintaining scientific integrity and patient safety.

---

1. Clinical Trial Phases & Experimental Designs

Oncology drug development follows a sequential four-phase clinical trial architecture:

Novel Master Protocol Designs

• Basket Trials: Test a single targeted therapy against a specific genomic mutation across multiple different histology tumor types (e.g., larotrectinib in NTRK fusion-positive solid tumors).
• Umbrella Trials: Test multiple different targeted therapies within a single tumor type, matched to individual patient biomarker profiles (e.g., non-small cell lung cancer umbrella protocols).
• Platform Trials: Multi-arm, perpetual trials allowing candidate drugs to enter or leave the infrastructure based on interim efficacy algorithms.

---

2. Bioethics, IRB Oversight & Informed Consent

Human subject protection in oncology research is governed by international ethical frameworks (Declaration of Helsinki, Belmont Report) and federal regulations (FDA Title 21 CFR, Common Rule 45 CFR 46).

Core Ethical Principles (Belmont Report)

1. Respect for Persons: Asserts individual autonomy. Requires voluntary informed consent without coercion or undue influence. Special protections must be extended to vulnerable populations (e.g., pediatric patients, prisoners, cognitively impaired, economically disadvantaged).
2. Beneficence: Obligates researchers to maximize potential benefits while minimizing potential risks ("Do no harm").
3. Justice: Mandates equitable selection of research subjects, ensuring fair distribution of research risks and benefits without demographic bias.

Institutional Review Board (IRB) Principles

• Every clinical trial protocol, consent form, patient questionnaire, and advertisement must receive prospective review and approval from an accredited Institutional Review Board (IRB).
• Informed Consent Process: Informed consent is an ongoing communication process, not merely signing a document. Patients must be informed of potential risks, benefits, alternative treatments (including SOC and palliative care), and their absolute right to withdraw consent at any time without compromising standard medical care.
• Protocol amendments, safety updates, and un-blinding requests require immediate IRB re-approval.

---

3. CTCAE v5.0 Adverse Event Grading & SAE Reporting

The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0) provides standardized definitions and severity grading for adverse events (AEs) occurring in oncology clinical trials.

Severity Grading Scale (Grades 1 to 5)

• Grade 1 (Mild): Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
• Grade 2 (Moderate): Minimal, local, or non-invasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADLs).
• Grade 3 (Severe): Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADLs.
• Grade 4 (Life-Threatening): Life-threatening consequences; urgent intervention indicated.
• Grade 5 (Death): Death related to the adverse event.

Serious Adverse Event (SAE) Reporting Rules

An Adverse Event (AE) is any untoward medical occurrence in a patient administered a pharmaceutical product, regardless of causal relationship. An AE is defined as a Serious Adverse Event (SAE) if it results in any of the following outcomes:

• Patient death
• Life-threatening event
• Inpatient hospitalization or prolongation of existing hospitalization
• Persistent or significant disability/incapacity
• Congenital anomaly / birth defect

APRN Protocol Action: All SAEs mandate expedited reporting within 24 hours of discovery to the trial sponsor, principal investigator, and IRB, regardless of attributed drug relationship.

---

4. Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

RECIST 1.1 provides standardized anatomical imaging criteria (CT/MRI) to assess objective tumor response in solid tumor clinical trials.

Baseline Target vs. Non-Target Lesion Selection

• Target Lesions: Maximum of 5 total lesions (and maximum of 2 lesions per organ) representative of all involved organs. Must be measurable at baseline:
  • Non-Nodal Lesions: Longest diameter $\ge 10 ext{ mm}$ on CT slice.
  • Pathological Lymph Nodes: Short axis $\ge 15 ext{ mm}$ on CT slice.
• Non-Target Lesions: All other lesions, including non-measurable disease (e.g., bone metastases, leptomeningeal disease, ascites, pleural effusion, or nodes with short axis $10–14 ext{ mm}$).

Categorical Tumor Response Criteria (Target Lesions)

$ext{Sum of Diameters (SoD)} = \sum ext{Longest Diameters of Non-Nodal Targets} + \sum ext{Short Axes of Target Nodes}$

---

5. Immune-Related Response Criteria (iRECIST)

Cancer immunotherapies (checkpoint inhibitors) can induce atypical response patterns, such as pseudoprogression—an initial increase in tumor burden or appearance of new lesions caused by intratumoral infiltration of activated lymphocytes, followed by delayed tumor regression.

Baseline Imaging & Target Lesion SoD Calculated
  │
  ▼
Follow-Up Imaging Demonstrates >= 20% Increase in SoD or New Lesion
  │
  ├── Standard RECIST 1.1: Classify as Progressive Disease (PD) -> Stop Trial Drug
  │
  └── iRECIST Guidelines: Classify as Immune Unconfirmed Progressive Disease (iUPD)
        │
        ▼
        Continue Immunotherapy & Re-Image in 4 to 8 Weeks
        │
        ├── Further Increase in SoD / New Lesions: Classify as iCPD (Confirmed PD) -> Discontinue
        └── Tumor Shrinkage / Stabilization: Classify as Pseudoprogression (PR/SD) -> Continue

• iUPD (Immune Unconfirmed Progressive Disease): Assigned upon initial observation of progression criteria. If the patient remains clinically stable, immunotherapy is continued, and a confirmation scan is performed 4 to 8 weeks later.
• iCPD (Immune Confirmed Progressive Disease): Assigned if the follow-up scan demonstrates further increase in tumor size or new lesions, confirming true progressive disease.